Clinical Trials
28 trialsEVEREST-2
A2 Biotherapeutics Inc.
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
ACTengine
Immatics US, Inc.
RAINFOL-03
Genmab
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
TROY
Yonsei University
EPOCA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
DUAL-OV-CAR-NK
Beijing Biotech
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
Spatially Fractionated Radiation Treatment for Gynaecological Cancers
Tata Memorial Hospital
Retro-COSMOS
Tata Memorial Hospital
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
NCG-Compliance
Tata Memorial Hospital
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
ON-5001
OncoNano Medicine, Inc.
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc.
CYCLOPS
CNAO National Center of Oncological Hadrontherapy
RACC
Karolinska Institutet
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
QLPPEC/GOG-003
Tianjin Medical University Cancer Institute and Hospital
CHIPRO
Chipscreen Biosciences, Ltd.
Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery
Cukurova University
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
Imperial College London
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University